Welcome to our dedicated page for Design Therapeutics SEC filings (Ticker: DSGN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Design Therapeutics, Inc. (DSGN) SEC filings page on Stock Titan provides access to the company’s publicly filed regulatory documents, along with AI-assisted summaries to help interpret key disclosures. As a clinical-stage biotechnology company listed on Nasdaq, Design Therapeutics files annual reports on Form 10-K, quarterly reports on Form 10-Q, and current reports on Form 8-K that describe its GeneTAC pipeline, financial condition, and material corporate events.
Form 10-K and 10-Q filings contain detailed information about research and development activities for programs such as DT-216P2 for Friedreich ataxia, DT-168 for Fuchs endothelial corneal dystrophy, DT-818 for myotonic dystrophy type-1, and the Huntington’s disease program. These reports typically discuss R&D expenses, operating results, risk factors related to clinical trials and regulatory interactions, and the company’s liquidity and capital resources. Stock Titan’s AI tools can highlight sections that relate to pipeline progress, clinical trial design, and genomic medicine strategy.
Form 8-K current reports are used by Design Therapeutics to disclose material events between periodic reports, such as quarterly financial results or changes in the Board of Directors. For example, 8-K filings have documented the appointment of a new director and the release of financial results for specific quarters. AI-generated overviews can help users quickly understand what each 8-K event means for the company’s operations and governance.
Investors can also review exhibits and references to other agreements, such as director compensation policies and indemnification agreements, which are cited in certain filings. The DSGN filings page updates as new documents are posted to the SEC’s EDGAR system, and AI summaries assist in navigating lengthy texts so users can focus on sections relevant to clinical-stage biotechnology and GeneTAC development.
Design Therapeutics director David Shapiro received new stock option awards, increasing his potential equity stake without any open-market trading. On March 31, 2026, he was granted options for 60,000 shares of common stock at an exercise price of $10.64 per share, expiring March 30, 2036. These options vest in equal monthly installments over 36 months following March 31, 2026. He also received a separate option for 7,500 shares at the same $10.64 exercise price, expiring March 30, 2036, vesting in equal monthly installments over 12 months following March 31, 2026. Both grants are reported as direct ownership and represent compensation awards rather than share purchases or sales.
Design Therapeutics, Inc. filed a Form 3 insider report identifying David Shapiro as a director of the company. The provided data shows no reportable transactions or holdings, indicating this filing serves only to register his status as a reporting person.
Design Therapeutics, Inc. reported that its Board appointed David Shapiro, M.D., as a Class III director effective March 31, 2026, with a term running until the 2027 annual meeting of stockholders. He will also serve on the Nominating and Corporate Governance Committee.
Under the company’s non-employee director compensation policy, Dr. Shapiro will receive an annual cash retainer of $40,000 for Board service and $5,000 for Nominating Committee service. He was granted an initial option to purchase 60,000 shares of common stock vesting monthly over three years and a prorated annual option for 7,500 shares vesting monthly over one year.
SR One Capital Fund I Aggregator, SR One Capital Partners I, SR One Capital Management and Simeon George filed an amended beneficial ownership report for Design Therapeutics, Inc. common stock. Aggregator, Partners I and Parent each report beneficial ownership of 6,526,476 shares, representing 10.6% of the outstanding common stock.
Dr. Simeon George reports beneficial ownership of 6,607,892 shares, or 10.7% of the class, including 81,416 shares over which he has sole voting and dispositive power and 6,526,476 shares over which he shares voting and dispositive power. The filing states that their percentage ownership decreased by more than 1% because the issuer’s outstanding common stock increased to 61,672,279 shares as of March 2, 2026, and notes that none of the reporting persons has traded the stock in the last 60 days.
Design Therapeutics, Inc. is a clinical-stage biopharma company developing GeneTAC small‑molecule genomic medicines to treat nucleotide repeat expansion diseases by modulating gene transcription at the DNA level. Its lead programs target Friedreich ataxia (FA), Fuchs endothelial corneal dystrophy (FECD), myotonic dystrophy type‑1 (DM1) and Huntington’s disease (HD).
Lead FA candidate DT‑216P2, a reformulation of DT‑216, is in the RESTORE‑FA Phase 1/2 multiple‑ascending dose trial after Phase 1 data showed FXN increases with the prior formulation and improved pharmacokinetics with DT‑216P2. An update on frataxin levels after 12 weeks of dosing is expected in the second half of 2026.
Eye‑drop candidate DT‑168 for FECD has completed a Phase 1 trial in healthy volunteers with favorable safety and is in a Phase 2 biomarker study, with data also expected in the second half of 2026. DM1 candidate DT‑818 has preclinical data showing over 90% toxic RNA foci reduction and has regulatory clearance for a Phase 1 MAD trial, with patient dosing planned in 2026. HD candidates have shown selective mutant huntingtin reduction in patient cells and a mouse model while preserving wild‑type huntingtin.
Design Therapeutics reported higher operating expenses and a wider loss in 2025 as it advanced multiple GeneTAC® programs. Research and development spending was $59.1 million for the year, up from $44.4 million, and net loss increased to $69.8 million from $49.6 million.
Fourth-quarter 2025 net loss was $16.0 million, or $0.27 per share. The company ended 2025 with $219.8 million in cash, cash equivalents and investment securities, which it expects will fund planned operations into 2029.
Clinically, Design continues dosing Friedreich ataxia patients with DT-216P2 and running a Phase 2 biomarker trial of DT-168 in Fuchs endothelial corneal dystrophy, with data from both anticipated in the second half of 2026. It plans to begin dosing myotonic dystrophy type-1 patients with DT-818 in a Phase 1 trial in the first half of 2026, with results expected in 2027, while also progressing preclinical work in Huntington’s disease.
Design Therapeutics, Inc. (DSGN) has a significant shareholder disclosure from Point72-related entities. Point72 Asset Management, Point72 Capital Advisors, and Steven A. Cohen report beneficial ownership of 5,372,004 shares of common stock, representing 9.4% of the class as of December 31, 2025.
The shares are held by Point72 Associates, an investment fund managed by Point72 Asset Management, which has investment and voting power under an investment management agreement. The reporting persons certify the stake was not acquired to change or influence control of Design Therapeutics.
Design Therapeutics, Inc. reported a governance change, stating that board member Deepa Prasad has decided to resign from the Company’s Board of Directors. Her resignation is effective February 1, 2026 and is attributed to conflict-avoidance policies tied to her newly appointed role with a major bank.
The filing does not describe any disagreement with the Company, instead framing the departure as a compliance requirement related to her new external position. Design Therapeutics remains listed on the Nasdaq Global Select Market under the ticker DSGN, with Pratik Shah continuing as President, Chief Executive Officer and Chairperson.
Design Therapeutics disclosed that its President, CEO and Chairperson, who also serves as a director, holds a stock option to purchase 525,000 shares of common stock at an exercise price of $2.48 per share, originally granted on September 1, 2023.
The option was subject to both time-based vesting and a specific performance condition. On December 9, 2025, the board determined that the performance condition had been met, causing 295,312 of these option shares to vest. The remaining unvested portion is scheduled to vest in equal monthly installments through August 25, 2027, as long as the executive continues to provide service to the company.
Design Therapeutics (DSGN) filed its Q3 10-Q, showing continued investment in its GeneTAC platform and clinical programs. Cash, cash equivalents and investment securities were $206.0 million as of September 30, 2025, and management states resources are sufficient for more than 12 months following issuance. Q3 operating expenses were $19.3 million (research and development $14.6 million; general and administrative $4.7 million), driving a Q3 net loss of $17.0 million. For the nine months, operating expenses totaled $61.3 million and net loss was $53.8 million.
The company is conducting the RESTORE-FA Phase 1/2 MAD trial of DT-216P2 in Friedreich ataxia and anticipates an update on FXN levels in the second half of 2026. In June 2025, the FDA placed a clinical hold on the DT-216P2 IND regarding the starting dose in the United States; the company plans to address the request. In FECD, Phase 2 biomarker data for DT-168 are anticipated in the second half of 2026. A third candidate, DT-818 for DM1, is cleared to begin a Phase 1 MAD trial in Australia in the first half of 2026.
As capital tools, a $300.0 million shelf (including an $100.0 million ATM) became effective in May 2025; no ATM sales occurred as of September 30, 2025. Common shares outstanding were 56,963,757 as of October 31, 2025.